Jin M L
Beijing Institute for Cancer Research.
Zhonghua Zhong Liu Za Zhi. 1989 Mar;11(2):130-2.
140 patients with advanced gastric cancer confirmed by pathology were treated by UFT (Uracil, FT-207) and mitomycin C (MMC) from Sept. 1985 to June 1987. All the patients received UFT #3 T. i. d. to a total dose of 30 g. Mitomycin C, 8-20 mg i. v. Q. wk was given to a total dose of 48-60 mg. Of the 140 patients, 65 had cancer of cardia, 36 cancer of gastric body, and 39 cancer of gastric antrum. There were 125 males and 15 females. The ages ranged from 30 to 80 years. In this series, CR was 10.0% and PR 44.3% with total remission rate of 54.3% (76/140). Thirty-four patients receiving UFT alone as control had a response rate of 26.5%. The response rate was higher in patients treated with UFTM than those with UFT alone. The median remission was 4 months. That main side effects were leukopenia and thrombocytopenia. The results showed that combination chemotherapy (UFTM) was valid in treating advanced gastric cancer.
1985年9月至1987年6月，对140例经病理确诊的晚期胃癌患者采用优福定（尿嘧啶、替加氟）和丝裂霉素C（MMC）进行治疗。所有患者口服优福定，每日3次，每次3片，总剂量30g。丝裂霉素C，静脉注射，每周1次，每次8 - 20mg，总剂量48 - 60mg。140例患者中，贲门癌65例，胃体癌36例，胃窦癌39例。男性125例，女性15例。年龄范围为30至80岁。在本系列中，完全缓解（CR）率为10.0%，部分缓解（PR）率为44.3%，总缓解率为54.3%（76/140）。34例仅接受优福定治疗作为对照的患者缓解率为26.5%。接受优福定联合丝裂霉素C治疗的患者缓解率高于仅接受优福定治疗的患者。中位缓解期为4个月。主要副作用为白细胞减少和血小板减少。结果表明，联合化疗（优福定联合丝裂霉素C）对晚期胃癌治疗有效。
